Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

Inclusion Criteria: * Written informed consent signed by the patient and guardian. * Positive clinical history of allergy to dust mites. * FEV1 greater than or equal to 80% of the expected value and improvement in FEV1 greater than 12% after bronchodilation. * Age-between 5 and 14 years. * Sensitization to dust mites, diagnosed by positive skin tests to Dermatophagoides pteronyssinus: wheal size \> 3 mm diameter and / or RAST (\> 0.7 kU / L). Exclusion Criteria: * Patients out of the age range. * Use of immunotherapy during the last four years. * Any contraindication for the use of immunotherapy in accordance with European Allergy and Clinical Immunology Immunotherapy Subcommittee criteria: * Treatment with ß-blockers * Patients who have a condition in which adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc..). * Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role * Patients suffering from immune deficiencies * Patients with serious psychiatric / psychological disturbances * Patients aspirin intolerance